Kestra Medical plans insider stock sale in 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. reported a planned sale of 5,391 shares of common stock through Merrill Lynch on the NASDAQ on 08/03/2026, with an indicated value of $128,312.27. The shares relate to performance share unit awards that vested on 07/17/2026 under the issuer’s equity compensation plan. In the prior three months, Vaseem Mahboob sold 3,980 shares for $90,560.62 on 07/30/2026 and 8,817 shares for $199,344.62 on 07/31/2026.
Key Figures
Key Terms
equity compensation plan financial
securities sold during the past 3 months regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock sale is Kestra Medical Technologies (KMTS) planning under this filing?
What recent KMTS stock sales by Vaseem Mahboob are disclosed?
AI-generated analysis. How Rhea-AI works. Not financial advice.